Skip to main content
Signal8
Launch Terminal

PALISADE BIO, INC. (PALI)

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Palisade Bio, Inc. logo

Palisade Bio, Inc.

NASDAQ:PALIHealthcare
-2.52%$1.16
AH$1.16+0.00%vs close
Mkt Cap$206.1M
Float–
O/S177.68M
Vol
$ Vol
RVOL
Inst Own97.5%
Earnings
Dilution
Palisade Bio, Inc. logoNASDAQ:PALI$1.16-2.52%
Upcoming Catalysts
  • PALI-2108READOUT
    Cash runway at this date: 5yr
    Fourth quarter of 2027~60w8-K
Phase Distribution
12 lead-sponsored trials·2 active·4 completed
Phase 16
Phase 24
Phase 31
Not applicable1
(1 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Terminated

    A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection

    LB1148, Placebo

    Ileus, Gastro-Intestinal Disorder

    Enrollment
    23
    Start
    Jun 2022
    Primary Completion
    Mar 2023
    Completion
    Aug 2023
    NCT05470387
  • Phase 2
    Unknown status

    Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis

    Human spinal cord stem cell implantation

    Amyotrophic Lateral Sclerosis

    Enrollment
    18
    Start
    May 2013
    Primary Completion
    Dec 2015est.
    Completion
    Nov 2016est.
    NCT01730716
  • Phase 2
    Unknown status

    Study of NSI-189 for Major Depressive Disorder

    80 Milligrams NSI-189, Placebo

    Major Depressive Disorder

    Enrollment
    220
    Start
    Mar 2016
    Primary Completion
    Jun 2017est.
    Completion
    Dec 2017est.
    NCT02695472
  • Phase 2
    Completed

    A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection

    LB1148, Placebo

    Ileus, Post-Operative Adhesions

    Enrollment
    112
    Start
    Oct 2019
    Primary Completion
    Sep 2023
    Completion
    Sep 2023
    NCT02836470
  • Phase 2
    Recruiting

    A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis

    PALI-2108, PALI-2108

    Ulcerative Colitis (UC), Severe Ulcerative Colitis +1

    Enrollment
    204
    Start
    Aug 2026
    Primary Completion
    Oct 2027est.
    Completion
    Jun 2028est.
    NCT07845487
  • Phase 1
    Completed

    Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189

    NSI-189 Phosphate

    Depression

    Enrollment
    35
    Start
    Feb 2011
    Primary Completion
    Nov 2011
    Completion
    Nov 2011
    NCT01310881
  • Phase 1
    Unknown status

    Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis

    surgical implantation

    Amyotrophic Lateral Sclerosis

    Enrollment
    18
    Start
    Jan 2009
    Primary Completion
    Dec 2015
    Completion
    Dec 2016est.
    NCT01348451
  • Phase 1
    Completed

    Multiple-Dose Pharmacokinetics (PK), and Pharmacodynamic (PD) Effect of NSI-189 Phosphate in Depression Patient Subjects

    NSI-189 Phosphate, microcrystalline cellulose capsules

    Depression

    Enrollment
    26
    Start
    May 2012
    Primary Completion
    Feb 2014
    Completion
    Feb 2014
    NCT01520649
  • Phase 1
    Unknown status

    Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI

    Human spinal cord stem cells.

    Spinal Cord Injury (SCI)

    Enrollment
    8
    Start
    Aug 2014
    Primary Completion
    Jul 2018est.
    Completion
    Dec 2022est.
    NCT01772810
  • Phase 1
    Completed

    Phase 1 Study Evaluating PALI-2108 in Healthy Volunteers and Ulcerative Colitis Patients.

    PALI-2108, PALI-2108 Placebo

    Ulcerative Colitis (UC), Healthy Volunteer

    Enrollment
    89
    Start
    Nov 2024
    Primary Completion
    Jul 2025
    Completion
    Aug 2025
    NCT06663605
  • Phase 1
    Active, not recruiting

    A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's Disease

    PALI-2108

    Fibrostenotic Crohn's Disease

    Enrollment
    6
    Start
    Oct 2025
    Primary Completion
    Jan 2026
    Completion
    Mar 2026est.
    NCT07428096
  • Observational
    Unknown status

    A Longitudinal Observational Cohort Study of NSI-189, With Out-Patients With Major Depressive Disorder

    NSI-189

    Major Depressive Disorder

    Enrollment
    220
    Start
    Aug 2016
    Primary Completion
    Dec 2017est.
    Completion
    Jan 2018est.
    NCT02724735
Search ClinicalTrials.gov for “Palisade Bio”